Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04627038 · ClinicalTrials.gov registry record · Phase 2
Chronic Pain Master Protocol (CPMP): A Study of LY3556050 in Participants With Osteoarthritis
A Phase 2 study of Osteoarthritis, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 2
- Development phase
- 202
- Enrollment target
- 20
- Study locations
NCT04627038 is a Phase 2 study of Osteoarthritis that has completed, run by Eli Lilly and Company. The registered enrollment target is 202 participants, below the 816-participant average among 135 other Osteoarthritis trials with a reported enrollment target (75% lower). The trial reports 20 study locations across 6 states.
The verdict
NCT04627038, a Phase 2 study of Osteoarthritis, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 202 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study is being done to test the safety and efficacy of LY3556050 for the treatment of osteoarthritis pain. This trial is part of the chronic pain master protocol, H0P-MC-CPMP (NCT05986292), which is a protocol to accelerate the development of new treatments for chronic pain.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG LY3556050
Study Locations (20)
Florida
- VIN-Julie Schwartzbard - Aventura
- Clinical Research of South Florida - Coral Gables
- Suncoast Research Group - Miami
- University of Miami Don Suffer Clinical Research Building - Miami
- New Horizon Research Center - Miami
- Renstar Medical Research - Ocala
- Synexus Clinical Research US, Inc - Orlando - Orlando
- Synexus Clinical Research - St. Petersburg - Pinellas Park
- Martin E. Hale M.D., P.A. - Plantation
- Synexus Clinical Research US, Inc. - The Villages
Arizona
- Synexus- Chandler - Chandler
- Synexus Clinical Research - Glendale - Glendale
- Alliance for Multispecialty Research - Clinical Research Consortium - Tempe
California
- Irvine Clinical Research - Irvine
- Artemis Institute for Clinical Research - Riverside
- Artemis Institute for Clinical Research - San Diego
Illinois
- Synexus Clinical Research - Chicago
- Northwestern University - Chicago
Alabama
- Simon Williamson Clinic - Birmingham
Connecticut
- CMR of Greater New Haven - Hamden
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 202 participants |
| Start Date | 2020-11-12 |
| Est. Completion | 2021-10-21 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04627038
The ClinicalTrials.gov registry entry for NCT04627038 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 202 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 816-participant average among 135 other Osteoarthritis trials with a reported enrollment target (75% lower). The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Osteoarthritis appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT04627038 reports 20 study locations spanning 6 distinct geographic areas - top geographies include Florida, Arizona, California.
Frequently Asked Questions
What is clinical trial NCT04627038 about?
NCT04627038 is a clinical study titled "Chronic Pain Master Protocol (CPMP): A Study of LY3556050 in Participants With Osteoarthritis". This study is being done to test the safety and efficacy of LY3556050 for the treatment of osteoarthritis pain. This trial is part of the chronic pain master protocol, H0P-MC-CPMP (NCT05986292), which is a protocol to accelerate the development of new treatments for chronic pain.
What is the current status of trial NCT04627038?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 202 participants. The study started on 2020-11-12. Estimated completion is 2021-10-21.
What conditions does trial NCT04627038 study?
This clinical trial studies the following conditions: Osteoarthritis.
What interventions are being tested in trial NCT04627038?
The interventions under investigation include: Placebo (DRUG), LY3556050 (DRUG).
Who is sponsoring clinical trial NCT04627038?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04627038 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Connecticut, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Osteoarthritis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Safety & Effectiveness of Autologous Regenerative Cell Therapy on Pain & Inflammation of Osteoarthritis of the Knee
RECRUITING · Phase 2
-
Safety & Effectiveness of Autologous Regenerative Cell Therapy on Pain & Inflammation of Osteoarthritis of the Shoulder
RECRUITING · Phase 2
-
Safety & Effectiveness of Autologous Regenerative Cell Therapy on Pain & Inflammation of Osteoarthritis of the Hip
RECRUITING · Phase 2
-
Platelet Rich Plasma Injections In Young And Old Human Subjects
RECRUITING · Phase 2
-
A Mobile Intervention to Reduce Pain and Improve Health-III
RECRUITING · Phase 2
-
An Study to Evaluate Safety and Tolerability of OA-SYS in Subjects With Moderate to Severe Osteoarthritis of the Knee Joint
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.